Navigation Links
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Date:10/10/2007

mory impairment (AAMI). Accera plans to self-commercialize Ketasyn as a medical food for the treatment of AD in the US in 2008. A key element of Accera's strategy is work with corporate partners to commercialize Ketasyn in non-U.S. markets, and to develop AC-1202 and other proprietary small molecule compounds in its pipeline for a range of memory and cognition disorders associated with neurological conditions and aging. http://www.accerapharma.com

About Ketasyn(TM)

Brain imaging techniques performed on Alzheimer's patients reveal a dramatically decreased uptake of glucose, the brain's preferred source of energy. Known as neuronal hypometabolism, this condition resembles diabetes in the brain, or Type III diabetes. Ketasyn(TM) (AC-1202) is an orally available, liquid compound that is efficiently converted into ketone bodies, an alternative energy source that the brain can use even when glucose metabolism is impaired. By preserving glucose-deprived neurons, Ketasyn demonstrates neuroprotective and disease modifying potential in a number other neurodegenerative diseases characterized by neuronal hypometabolism. This first-in-class compound is also being evaluated in age-associated memory impairment, Parkinson's disease, and selected orphan drug indications.

About Medical Foods

The Food and Drug Administration defines a medical food as a food to be consumed or administered orally under medical supervision for the dietary management of a disease or condition for which specific nutritional requirements have been scientifically proven. Medical foods are specially formulated and processed to meet these nutritional requirements, which modification of the diet alone cannot satisfy. Medical foods may be prescribed by a physician for a patient actively receiving medical attention for a specific disease or condition, and are subject to the general food and safety labeling requirements of the Federal
'/>"/>

SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... listed in the management information circular dated June 1, ... Meeting of Shareholders, held earlier today, June 26 ... 5 nominees proposed by management were elected as ... Company,s next Annual Meeting of Shareholders or until ...
(Date:6/26/2015)... , June 23, 2015 ... announced the addition of the "Global Cancer ... offering. Market introduction of cancer biosimilar ... and commercialization potential. Chemotherapeutic drugs have dominated the ... modalities have been introduced in past few years. ...
(Date:6/25/2015)... 25, 2015 ... announced the addition of the  "2015 ... Cancer Diagnostics Industry: Oncogenes, Biochemical Markers, ... Commercial Labs, POC Locations"  report ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , A ...
(Date:6/25/2015)... NEW YORK , June 25, 2015  The ... , Professor of Genome Sciences and Medical Genetics at ... the 2015 Pro Bono Humanum Award at the ninth ... ceremony.   The Pro Bono ... Professor King is the first woman recipient of the ...
Breaking Biology Technology:iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 2iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders 3Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 2Analysis of the Global Cancer Diagnostics Industry 2015-2020: Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains 3The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 2The Prix Galien USA Awards Committee Selects Professor Mary-Claire King as 2015 Pro Bono Humanum Honoree 3
... (Pink Sheets: BIEL), announced today that the ... sale by its,distributor, Endotherapeutics Party Limited. ... professionals of,Endotherapeutics will successfully launch ActiPatch in ... of experience in the,medical devices market and ...
... ... REDWOOD CITY, Calif., Oct. 9 Ingenuity Systems, ... science researchers,generate insights from biological and chemical information, ... to help researchers understand metabolomics data in the,context ...
... Drug Pipeline and Advancement of Clinical Programs, ... Inc.,(OTC Bulletin Board: AVGO), a late-stage biotechnology company ... today that it will be a presenting company ... held October 9-11, 2007 at the,Palace Hotel of ...
Cached Biology Technology:Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Ingenuity Systems Launches New Metabolomics Solution Within IPA 2Avicena to Present at 4th Annual BIO InvestorForum Conference 2
(Date:6/15/2015)... , Jun. 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces that its leading ... to media at Digital Experience! @ NYC June 18th. ... of the latest innovation in technology to over 300 of ... held at the Metropolitan Pavilion in New York ...
(Date:6/10/2015)... , June 10, 2015 ... "3D Sensor Market by Technology (Ultrasound, TOF, Structured ... (consumer Electronics, Entertainment, Automotive) and by Geography - ... by MarketsandMarkets, the market is expected to reach ... of 25.51% between 2015 and 2020. ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... clinical data featuring its Precision Cancer Monitoring SM platform ... Liquid Biopsies conference in San Diego, CA ... Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... June 13-16. "We continue to advance our ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 33D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... studied the marine trophic network in Mauritania, on the ... heavily exploited fishing area, as well as being home ... marine mammal the monk seal and the Atlantic ... industrial and traditional fishing activities along the coast are ...
... -- NASA,s newest Earth-observing research mission is nearing launch. ... the sun and tiny atmospheric particles called aerosols affect ... long-term solar measurements needed to address key uncertainties about ... from Vandenberg Air Force Base in California on Feb. ...
... a hormone best known for stimulating the production of red ... published by Cell Press in the January 27th issue of ... contrasting influences on infectious and inflammatory diseases and may be ... is a cytokine hormone that stimulates the production of red ...
Cached Biology News:Monk seal and hump-backed dolphin are threatened by fishing activities off coast of Mauritania 2NASA prepares to launch next Earth-observing satellite mission 2NASA prepares to launch next Earth-observing satellite mission 3Red blood cell hormone modulates the immune system 2
MAb to Myoglobin Cardiac...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: